Too Hard For Investors To Understand
After teaching high school biology for 30 years (biology I, biology II, advanced placement; plus conduct of extensive student science research program [many awards, scholarships]), and also having done a good deal of technical science writing for lay audiences on my other areas of biological expertise, I can affirm that the details of the mechanism(s) of action of the Anavex molecules in dysfunctioning neurons simply will not be conveyed to lay audiences.
Telling that a “Alzheimer’s vaccine” shows early good results resonates quickly with readers of all competencies. Makes sense. Entirely plausible — therefore must be so.
But trying to convey the mechanism of action any of the Anavex sigma-1 receptor agonists in a simple word or phrase can’t happen; is beyond comprehension by lay audiences. Too hard to tell about. Too hard to understand. Therefore, probably just phony science gibberish and doesn’t really work. Some obscure “scientists” trying, once again, to snooker investors with high-sounding biological verbiage. Nice try. We are too smart to believe (or understand) any of it.
But, a vaccine? Yea! That’s what’s needed. Where can I get some shares of that?
We can jabber all we want about the current state of Anavex Life Sciences Corp and its science and depressed share price (the major posting topics here for months). But nothing is going to increase the price of an AVXL share until things the general public can understand appear. And those will be reports of Anavex 2-73 efficacies against any of the three conditions being tested in the clinical trials. Nothing hard to understand. Little girls with Rett syndrome have mothers telling how much better the girls are. Some Parkinson’s patients walk with reduced spasticity and increased motor control. Some Alzheimer’s patients begin to sleep soundly.
At worst, nothing is known for the investment public to act on until at least one of the trials is completed and formal results are announced. More likely, preliminary positive “results” (anecdotes) will “leak” with tangential news reports, perhaps from Australia.
Until either of those appear, formal or anecdotal reports of patient responses to Anavex 2-73, it’ll be more of the same on this message board. I follow the postings here each day. But none of them (with perhaps the exception of this one itself — ha) portends any accurate AVXL future in the near term.
Can only wait....
AI
